Antigenic properties of a novel vaccine strain for type Asia1 foot-and-mouth disease in pigs

Shin, Sung Ho; Jo, Hyundong; Ko, Mi-Kyeong; Choi, Joo-Hyung; You, Su-Hwa; Jo, Hye-Eun; Lee, Min Ja; Kim, Su-Mi; Kim, Byounghan

doi:10.1016/j.vetmic.2020.108802

Cited by 6 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The difference in the surface structure (VP1 G-H loop) between JC-VP1 and PA2-VP1 was determined through the molecular biological structural modeling of the recombinant virus capable of broad-spectrum defense ( Supplementary Figure S2A,B ). Mutations in the 3B region caused by replacing 3B 1 B 2 with two iterations of 3B 3 in the viral genome can be used as markers to distinguish vaccine viruses from wild-type strains [ 22 , 23 ].…”

Section: Resultsmentioning

confidence: 99%

Evaluation of Vaccine Strains Developed for Efficient, Broad-Range Protection against Foot-and-Mouth Disease Type O

et al. 2023

Self Cite

View full text Add to dashboard Cite

Foot-and-mouth disease (FMD) type O includes 11 genetic topotypes. The Southeast Asia (SEA), Middle East–South Asia (ME-SA), and Cathay topotypes belong to FMD type O and occur frequently in Asia. Therefore, it is necessary to develop a potent vaccine strain with a broad antigenic coverage in order to provide complete protection against these three topotypes. In this study, an experimental vaccine was produced using chimeric vaccine strains (JC-VP1 or PA2-VP1) that contained VP4, VP2, and VP3 of the ME-SA topotype (O Manisa) and VP1 of the SEA topotype (Mya98 lineage; O/SKR/Jincheon/2014) or ME-SA topotype (PanAsia2 lineage; O/PAK/44). Mice were immunized with the experimental vaccines, and they were fully protected against the three topotypes. The neutralizing antibody titers of PA2-VP1 were significantly higher than those of JC-VP1 in the early vaccination phase in pigs. Here, we confirmed complete protection in pigs vaccinated with JC-VP1 or PA2-VP1, when challenged against the SEA (O/SKR/Jincheon/2014), ME-SA (O/SKR/Boeun/2017) and Cathay (O/Taiwan/97) topotype viruses, with moderately higher protection provided by PA2-VP1 than by JC-VP1.

show abstract

Section: Resultsmentioning

confidence: 99%

Evaluation of Vaccine Strains Developed for Efficient, Broad-Range Protection against Foot-and-Mouth Disease Type O

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…The viral particles were recovered from cDNA-transfected cells. As in previous studies [ 11 ], the 3B1B2 segment in the viral genome was replaced with two 3B3 segments, and the chimeric and wild-type viruses were distinguished using a simple antigen diagnostic kit (lateral flow device) capable of detecting NSP through the lack of reaction at the replaced site. In addition, electron microscopy was used to confirm that the chimeric viruses were 25 nm in diameter and thus similar in size to wide-type viruses ( Figure 1 b).…”

Section: Resultsmentioning

confidence: 99%

“…The vaccine to be tested was prepared using the same procedure as described in a previous study [ 11 ]. Briefly, in order to prepare a vaccine for a single dose for pigs, 15 μg of each of the purified Apo22 and Apo22-B 146S antigens were individually mixed with ISA 206VG (Seppic, Paris, France) at a ratio of 1:1 ( v / v ).…”

Section: Methodsmentioning

confidence: 99%

Evaluation of a Vaccine Candidate Designed for Broad-Spectrum Protection against Type A Foot-and-Mouth Disease in Asia

Shin,

Hwang,

Kim

et al. 2024

Vaccines

Self Cite

View full text Add to dashboard Cite

Foot-and-mouth disease (FMD) vaccines are currently the most powerful protective and preventive measures used to control FMD. In this study, the chimeric vaccine strain containing antigenic epitopes from the FMD virus serotype A, which belongs to the ASIA topotype, was produced and evaluated. The chimeric vaccine strains contain sea-97/G1 (VP4, VP2, VP3) and A22 Iraq (VP1) or G-VII (VP1) for use in FMD vaccines in Asia. The 50% protective dose was determined in mice. Vaccinated mice were challenged with three different type A viruses (Sea-97/G1, Sea-97/G2, G-VII clade) seven days post-vaccination (dpv), and mice that received the vaccine candidates were protected against the three viruses. The protective capability of one of the vaccine candidates was evaluated in pigs. Vaccinated pigs were challenged with three different type A viruses (Sea-97/G1, Sea-97/G2, G-VII clade) at 28 dpv, and pigs that received the vaccine candidate were protected against the three viruses. The results showed that this vaccine candidate, which was designed to provide protection against FMD in Asia, efficiently protected pigs against virus challenge and thus has potential as a broad-spectrum vaccine for various epidemic FMD viruses.

show abstract

“…If a domestic FMD vaccine factory is built in the near future, it will be necessary to construct its own antigen bank. Therefore, the recombinant Asia1 vaccine strain, called Asia1 Shamir-R, was previously developed [ 8 ]. This study aimed to determine whether Asia1 Shamir-R can be commercially utilized for the FMD vaccine.…”

Section: Discussionmentioning

confidence: 99%

“…Since the Asia1 G-VIII that was reported in 2017 in Asia, was found to match with the Asia1 Shamir vaccine, which is known to be the only international vaccine strain of Asia1, the recombinant Asia1 Shamir vaccins strain (Asia1 Shamir-R) was constructed and shown to provide protection against Asia1 Shamir [ 8 ]. This study aimed to determine whether Asia1 Shamir-R can be commercially utilized for the FMD vaccine.…”

Section: Introductionmentioning

confidence: 99%

Determination of Optimal Antigen Yield and Virus Inactivation Conditions for the Production of the Candidate Foot-and-Mouth Disease Recombinant Vaccine Strain Asia1 Shamir-R in a Bioreactor

Kim,

Park,

Lee

et al. 2024

Viruses

Self Cite

View full text Add to dashboard Cite

Since the foot-and-mouth disease (FMD) outbreak in South Korea in 2010–2011, vaccination policies utilizing inactivated FMD vaccines composed of types O and A have been implemented nationwide. However, because type Asia1 occurred in North Korea in 2007 and intermittently in neighboring countries, the risk of type Asia1 introduction cannot be ruled out. This study evaluated the antigen yield and viral inactivation kinetics of the recombinant Asia1 Shamir vaccine strain (Asia1 Shamir-R). When Asia1 Shamir-R was proliferated in shaking flasks (1 L), a 2 L bioreactor (1 L), and a wave bioreactor (25 L), the antigen yields were 7.5 μg/mL, 5.2 μg/mL, and 3.8 μg/mL, respectively. The optimal FMDV inactivation conditions were 2 mM BEI at 26 °C and 1.0 mM BEI at 37 °C. There was no antigen loss due to BEI treatment, and only a decrease in antigen levels was observed during storage. The sera from pigs immunized with antigen derived from a bioreactor exhibited a neutralizing antibody titer of approximately 1/1000 against Asia1 Shamir and Asia1/MOG/05 viruses; therefore, Asia1 Shamir-R is expected to provide sufficient protection against both viruses. If an FMD vaccine production facility is established, this Asia1 Shamir-R can be employed for domestic antigen banks in South Korea.

show abstract

Antigenic properties of a novel vaccine strain for type Asia1 foot-and-mouth disease in pigs

Cited by 6 publications

References 18 publications

Evaluation of Vaccine Strains Developed for Efficient, Broad-Range Protection against Foot-and-Mouth Disease Type O

Evaluation of Vaccine Strains Developed for Efficient, Broad-Range Protection against Foot-and-Mouth Disease Type O

Evaluation of a Vaccine Candidate Designed for Broad-Spectrum Protection against Type A Foot-and-Mouth Disease in Asia

Determination of Optimal Antigen Yield and Virus Inactivation Conditions for the Production of the Candidate Foot-and-Mouth Disease Recombinant Vaccine Strain Asia1 Shamir-R in a Bioreactor

Contact Info

Product

Resources

About